Immunotherapy of Brain Tumors

Progress in Tumor Research

Volumn 42, Issue , 2015, Pages 11-21

  Dutoit, Valérie ^a   Migliorini, Denis ^b   Walker, Paul R ^a   Dietrich, Pierre Yves ^b  

^a Laboratory of Tumor Immunology   (United States)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CHIMERIC ANTIGEN RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; IMMUNE CHECKPOINT INHIBITOR; INTERLEUKIN 13 RECEPTOR ALPHA2; ISOCITRATE DEHYDROGENASE 1; PEPTIDE; TRANSFORMING GROWTH FACTOR BETA; TUMOR PROTEIN; VITESPEN; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; TUMOR ANTIGEN;

ADVANCED CANCER; ARTICLE; CANCER IMMUNOTHERAPY; CELL THERAPY; CHIMERIC ANTIGEN RECEPTOR T-CELL IMMUNOTHERAPY; CLINICAL TRIAL (TOPIC); DENDRITIC CELL; GLIOMA; HUMAN; IMMUNE RESPONSE; NONHUMAN; PATIENT SAFETY; REGULATORY T LYMPHOCYTE; T CELL DEPLETION; TUMOR MICROENVIRONMENT; ADULT; BRAIN NEOPLASMS; IMMUNOLOGY; IMMUNOTHERAPY;

ADULT; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CANCER VACCINES; HUMANS; IMMUNOTHERAPY;

EID: 84965084592     PISSN: 22961895     EISSN: 22961887     Source Type: Book Series    
DOI: 10.1159/000436986     Document Type: Article

References (48)

1. Woodworth GF, Dunn GP, Nance EA, Hanes J, Brem H: Emerging insights into barriers to effective brain tumor therapeutics. Front Oncol 2014;4:126.
2. Ohgaki H, Kleihues P: The definition of primary and secondary glioblastoma. Clin Cancer Res 2013;19:764-772.
3. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-996.
4. Reardon DA, Wucherpfennig KW, Freeman G, Wu CJ, Chiocca EA, Wen PY, et al. An update on vaccine therapy and other immunotherapeutic approaches for glioblastoma. Expert Rev Vaccines 2013;12:597-615.
5. Lizee G, Overwijk WW, Radvanyi L, Gao J, Sharma P, Hwu P: Harnessing the power of the immune system to target cancer. Annu Rev Med 2013;64:71-90.
6. Fridman WH, Pages F, Sautes-Fridman C, Galon J: The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 2012;12:298-306.
7. Mellman I, Coukos G, Dranoff G: Cancer immunotherapy comes of age. Nature 2011;480:480-489.
8. Schreiber RD, Old LJ, Smyth MJ: Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011;331:1565-1570.
9. Carson MJ, Doose JM, Melchior B, Schmid CD, Ploix CC: CNS immune privilege: hiding in plain sight. Immunol Rev 2006;213:48-65.
10. Calzascia T, Masson F, Berardino-Besson W, Contassot E, Wilmotte R, Aurrand-Lions M, et al. Homing phenotypes of tumor-specific CD8 T cells are predetermined at the tumor site by crosspresenting APCs. Immunity 2005;22:175-184.
11. Masson F, Calzascia T, Berardino-Besson W, de Tribolet N, Dietrich PY, Walker PR: Brain microenvironment promotes the final functional maturation of tumor-specific effector CD8+ T cells. J Immunol 2007;179:845-853.
12. Restifo NP, Dudley ME, Rosenberg SA: Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol 2012;12:269-281.
13. Sampson JH, Archer GE, Mitchell DA, Heimberger AB, Bigner DD: Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma. Semin Immunol 2008;20:267-275.
14. Sampson JH, Archer GE, Mitchell DA, Heimberger AB, Herndon JE, Lally-Goss D, et al. An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme. Mol Cancer Ther 2009;8:2773-2779.
15. Sampson JH, Heimberger AB, Archer GE, Aldape KD, Friedman AH, Friedman HS, et al. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol 2010;28:4722-4729.
16. Choi BD, Archer GE, Mitchell DA, Heimberger AB, McLendon RE, Bigner DD, et al. EGFRvIII-targeted vaccination therapy of malignant glioma. Brain Pathol 2009;19:713-723.
17. Schumacher T, Bunse L, Pusch S, Sahm F, Wiestler B, Quandt J, et al. A vaccine targeting mutant IDH1 induces antitumour immunity. Nature 2014;512:324-327.
18. Rammensee HG, Singh-Jasuja H: HLA ligandome tumor antigen discovery for personalized vaccine approach. Expert Rev Vaccines 2013;12:1211-1217.
19. Vonderheide RH, Nathanson KL: Immunotherapy at large: the road to personalized cancer vaccines. Nat Med 2013;19:1098-1100.
20. +T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with α-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. J Clin Oncol 2011;29:330-336.
21. Phuphanich S, Wheeler CJ, Rudnick JD, Mazer M, Wang H, Nuno MA, et al. Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma. Cancer Immunol Immunother 2013;62:125-135.
22. Terasaki M, Shibui S, Narita Y, Fujimaki T, Aoki T, Kajiwara K, et al. Phase I trial of a personalized peptide vaccine for patients positive for human leukocyte antigen-A24 with recurrent or progressive glioblastoma multiforme. J Clin Oncol 2011;29:337-344.
23. Pollack IF, Jakacki RI, Butterfield LH, Hamilton RL, Panigrahy A, Potter DM, et al. Antigen-specific immune responses and clinical outcome after vaccination with glioma-associated antigen peptides and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in children with newly diagnosed malignant brainstem and nonbrainstem gliomas. J Clin Oncol 2014;32:2050-2058.
24. Dutoit V, Herold-Mende C, Hilf N, Schoor O, Beckhove P, Bucher J, et al. Exploiting the glioblastoma peptidome to discover novel tumour-associated antigens for immunotherapy. Brain 2012;135:1042-1054.
25. Ahmed AU, Auffinger B, Lesniak MS: Understanding glioma stem cells: rationale, clinical relevance and therapeutic strategies. Expert Rev Neurother 2013;13:545-555.
26. Swartz AM, Li QJ, Sampson JH: Rindopepimut: a promising immunotherapeutic for the treatment of glioblastoma multiforme. Immunotherapy 2014;6:679-690.
27. Prins RM, Soto H, Konkankit V, Odesa SK, Eskin A, Yong WH, et al. Gene expression profile correlates with T cell infiltration and survival in glioblastoma patients vaccinated with dendritic cell immunotherapy. Clin Cancer Res 2011;17:1603-1615.
28. Prins RM, Soto H, Konkankit V, Odesa SK, Eskin A, Yong WH, et al. Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy. Clin Cancer Res 2011;17:1603-1615.
29. Kong S, Sengupta S, Tyler B, Bais AJ, Ma Q, Doucette S, et al. Suppression of human glioma xenografts with second-generation IL13R-specific chimeric antigen receptor-modified T cells. Clin Cancer Res 2012;18:5949-5960.
30. Brown CE, Starr R, Aguilar B, Shami AF, Martinez C, D'Apuzzo M, et al. Stem-like tumor-initiating cells isolated from IL13Rα2 expressing gliomas are targeted and killed by IL13-zetakine-redirected T Cells. Clin Cancer Res 2012;18:2199-2209.
31. Chow KK, Naik S, Kakarla S, Brawley VS, Shaffer DR, Yi Z, et al. T cells redirected to EphA2 for the immunotherapy of glioblastoma. Mol Ther 2013;21:629-637.
32. Ahmed N, Salsman VS, Kew Y, Shaffer D, Powell S, Zhang YJ, et al. HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumors. Clin Cancer Res 2010;16:474-485.
33. Hegde M, Corder A, Chow KK, Mukherjee M, Ashoori A, Kew Y, et al. Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma. Mol Ther 2013;21:2087-2101.
34. Ohno M, Ohkuri T, Kosaka A, Tanahashi K, June CH, Natsume A, et al. Expression of miR-17-92 enhances anti-tumor activity of T-cells transduced with the anti-EGFRvIII chimeric antigen receptor in mice bearing human GBM xenografts. J Immunother Cancer 2013;1:21.
35. Shen CJ, Yang YX, Han EQ, Cao N, Wang YF, Wang Y, et al. Chimeric antigen receptor containing ICOS signaling domain mediates specific and efficient antitumor effect of T cells against EGFRvIII expressing glioma. J Hematol Oncol 2013;6:33.
36. Sampson JH, Choi BD, Sanchez-Perez L, Suryadevara CM, Snyder DJ, Flores CT, et al. EGFRvIII mCAR-modified T-cell therapy cures mice with established intracerebral glioma and generates host immunity against tumor-antigen loss. Clin Cancer Res 2014;20:972-984.
37. Platten M, Ochs K, Lemke D, Opitz C, Wick W: Microenvironmental clues for glioma immunotherapy. Curr Neurol Neurosci Rep 2014;14:440.
38. Tran Thang NN, Derouazi M, Philippin G, Arcidiaco S, Berardino-Besson W, Masson F, et al. Immune Infiltration of Spontaneous Mouse Astrocytomas Is Dominated by Immunosuppressive Cells from Early Stages of Tumor Development. Cancer Res 2010;70:4829-4839.
39. Sampson JH, Schmittling RJ, Archer GE, Congdon KL, Nair SK, Reap EA, et al. A pilot study of IL-2Rα blockade during lymphopenia depletes regulatory T-cells and correlates with enhanced immunity in patients with glioblastoma. PLoS One 2012;7:e31046.
40. Le DT, Jaffee EM: Regulatory T-cell modulation using cyclophosphamide in vaccine approaches: a current perspective. Cancer Res 2012;72:3439-3444.
41. Kohanbash G, Okada H: Myeloid-derived suppressor cells (MDSCs) in gliomas and glioma-development. Immunol Invest 2012;41:658-679.
42. Huang Y, Goel S, Duda DG, Fukumura D, Jain RK: Vascular normalization as an emerging strategy to enhance cancer immunotherapy. Cancer Res 2013;73:2943-2948.
43. Fricke I, Mirza N, Dupont J, Lockhart C, Jackson A, Lee JH, et al. Vascular endothelial growth factor-trap overcomes defects in dendritic cell differentiation but does not improve antigen-specific immune responses. Clin Cancer Res 2007;13:4840-4848.
44. Chowdhary S, Chamberlain M: Bevacizumab for the treatment of glioblastoma. Expert Rev Neurother 2013;13:937-949.
45. Luwor RB, Stylli SS, Kaye AH: The role of Stat3 in glioblastoma multiforme. J Clin Neurosci 2013;20:907-911.
46. Pardoll DM: The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12:252-264.
47. Wilmotte R, Burkhardt K, Kindler V, Belkouch MC, Dussex G, Tribolet N, et al. B7-homolog 1 expression by human glioma: a new mechanism of immune evasion. Neuroreport 2005;16:1081-1085.
48. Ott PA, Hodi FS, Robert C: CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. Clin Cancer Res 2013;19:5300-5309.